1.93  0.21 (12.21%)		06-18 16:00
Open: 1.76 High: 1.96 Volume: 1,142,232		Pre. Close: 1.72 Low: 1.735 Market Cap: 86(M)

Short term
Mid term
Targets	6-month :	2.56	1-year :	2.99
Resists	First :	2.19	Second :	2.56
Pivot price	1.8
Supports	First :	1.84	Second :	1.62
MAs	MA(5) :	1.76	MA(20) :	1.81
	MA(100) :	1.53	MA(250) :	1.72
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	31	D(3) :	20.8
RSI	RSI(14): 59.4
52-week	High :	2.56	Low :	1.14

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ OSTX ] has closed below upper band by 21.6%. Bollinger Bands are 20.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.96 - 1.97	1.97 - 1.98
Low:	1.71 - 1.72	1.72 - 1.73
Close:	1.91 - 1.93	1.93 - 1.94

OS Therapies Incorporated is a clinical-stage biopharmaceutical company dedicated to identifying, advancing, and commercializing therapeutic solutions for osteosarcoma and other solid tumors within the United States. Its pipeline highlights OST-HER2, a readily available immunotherapy developed for osteosarcoma patients, alongside OST-tunable drug conjugate (OST-tADC). This innovative antibody-drug conjugate technology leverages a modular 'plug-and-play' platform equipped with customizable, pH-sensitive silicone linkers. Established in 2018, OS Therapies Incorporated is headquartered in Rockville, Maryland.

Tue, 02 Jun 2026
OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings - Benzinga

Fri, 29 May 2026
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World - TMX Newsfile

Fri, 29 May 2026
OST-HER2 osteosarcoma immunotherapy seeks FDA accelerated approval, ASCO data due - Stock Titan

Tue, 26 May 2026
Cancer survival data to be shared as OS Therapies visits multiple 2026 conferences - Stock Titan

Thu, 14 May 2026
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor - TMX Newsfile

Tue, 12 May 2026
Cancer therapy OST-HER2 faces 2026 EMA call after survival data - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.